Physician profile
Travis William Swink
NPI 1619060977
$2,111.12
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $575 · 2020: $148 · 2021: $298 · 2022: $681 · 2023: $410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $410.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $409.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $325.81 | 2019-2023 | Farxiga |
| Supernus Pharmaceuticals, INC. | $249.49 | 2019-2022 | |
| Amgen INC. | $193.39 | 2019-2022 | |
| Novo Nordisk INC | $168.31 | 2019-2023 | Wegovy |
| Janssen Pharmaceuticals, INC | $132.64 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $126.28 | 2019-2023 | Eliquis |
| Teva Pharmaceuticals USA, INC. | $123.33 | 2022-2023 | Austedo |
| Astellas Pharma US INC | $111.91 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $80.23 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $61.21 | 2022-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $55.84 | 2022 | |
| Abbvie INC. | $55.15 | 2023 | Vraylar |
| Ironshore Pharmaceuticals INC. | $50.82 | 2019-2021 | |
| Abbott Laboratories | $40.31 | 2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Lilly USA, LLC | $37.54 | 2022-2023 | Mounjaro |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $34.82 | 2019 | |
| Exact Sciences Corporation | $32.33 | 2023 | Cologuard Collection Kit |
| Neurocrine Biosciences, INC. | $31.52 | 2022-2023 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $26.65 | 2022 | |
| Alkermes, INC. | $21.66 | 2023 | Lybalvi |
| Corium, LLC | $21.31 | 2022 | |
| Idorsia Pharmaceuticals US INC | $17.86 | 2023 | Quviviq |
| Almatica Pharma LLC | $17.72 | 2022 | |
| Merck Sharp & Dohme LLC | $17.20 | 2020 | |
| Sanofi-Aventis U.S. LLC | $14.82 | 2020 | |
| Lundbeck LLC | $13.74 | 2023 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $12.65 | 2022 | |
| Pfizer INC. | $12.28 | 2019 | |
| Radius Health, INC. | $12.26 | 2020 | |
| Glaxosmithkline, LLC. | $12.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Travis Swink listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.